Answers are grounded in this paper and cite their sources.
Understanding the durability of vaccine-induced immunity is critical for evaluating long-term protection and vaccine scheduling, particularly in aging populations where immunosenescence may alter immune response dynamics. In this study, we used a novel mathematical modelling pipeline to quantify age-related differences in the contraction and persistence phases of gE-specific CD4+ T cell and anti-gE antibody responses following Shingrix vaccination. Specifically, we developed a semi-mechanistic model to expand virtual populations that captured inter-individual variability in peak concentrations and waning dynamics. To compare immune responses across age groups, we introduced a time varying, age-related immune advantage metric that measures the probability of a randomly selected younger individual exhibiting a stronger immune response than one from an older group. By evaluating this metric across multiple simulated virtual populations, our results demonstrate clear and sustained age-related differences in both gE-specific CD4+ T cells and anti-gE antibody responses, with younger age groups consistently exhibiting higher responses. Given these age-related differences, we used our model to explore alternative vaccine schedules in older age groups. These exploratory simulations suggest that booster doses administered between 6 and 12 months following the second dose may mitigate age-related differences in antibody dynamics. This work highlights the use of mechanistic mathematical modelling to disentangle age-associated differences in vaccine outcomes and lead to designing of plausible improvement in age-specific vaccine schedules.
No takes yet. Share an insight, caveat, or question.
Easlick et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: